Tenax Therapeutics, Inc. Common Stock TENX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-04T04:46:12.162Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-04T00:33:06.917612216Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-04T04:46:11.759999+00:00
Tenax Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | ||||||
| 50Δ | ||||||
| 55Δ | 1.78 | 139.7% | 11.7% | 2.01 | 153.6% | 9.2% |
| 60Δ | 1.71 | 149.9% | 10.6% | 2.08 | 147.5% | 8.0% |
| 65Δ | 1.64 | 160.1% | 9.5% | 2.16 | 141.4% | 6.7% |
| 70Δ | 1.58 | 170.3% | 8.4% | 2.23 | 135.4% | 5.5% |
| 75Δ | 1.51 | 180.5% | 7.3% | 2.31 | 129.3% | 4.3% |
| 80Δ | 1.38 | 190.2% | 5.8% | 2.38 | 123.3% | 3.0% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- 1.78
- IV
- 139.7%
- B/E move
- 11.7%
- Pseudo strike
- 2.01
- IV
- 153.6%
- B/E move
- 9.2%
60Δ
- Pseudo strike
- 1.71
- IV
- 149.9%
- B/E move
- 10.6%
- Pseudo strike
- 2.08
- IV
- 147.5%
- B/E move
- 8.0%
65Δ
- Pseudo strike
- 1.64
- IV
- 160.1%
- B/E move
- 9.5%
- Pseudo strike
- 2.16
- IV
- 141.4%
- B/E move
- 6.7%
70Δ
- Pseudo strike
- 1.58
- IV
- 170.3%
- B/E move
- 8.4%
- Pseudo strike
- 2.23
- IV
- 135.4%
- B/E move
- 5.5%
75Δ
- Pseudo strike
- 1.51
- IV
- 180.5%
- B/E move
- 7.3%
- Pseudo strike
- 2.31
- IV
- 129.3%
- B/E move
- 4.3%
80Δ
- Pseudo strike
- 1.38
- IV
- 190.2%
- B/E move
- 5.8%
- Pseudo strike
- 2.38
- IV
- 123.3%
- B/E move
- 3.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 183.32% | |
| 127.64% | |
| 233.01% | |
| 140.95% | |
| 201.83% | |
| 237.68% | |
| 178.12% | |
| 185.67% | |
| 137.95% | |
| 166.85% |
Biotechnology
TGTX
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and…
More →TNGX
Tango Therapeutics Inc. is a leading clinical-stage biotechnology firm at the forefront of cancer treatment innovation, specializing in synthetic lethality and targeted therapies.…
More →TNXP
Tonix Pharmaceuticals Holding Corp. The company is headquartered in Chatham, New Jersey.
More →TNYA
Tenaya Therapeutics Inc. is a pioneering clinical-stage biotechnology firm that is revolutionizing the treatment of heart disease through its proprietary engineered heart cell…
More →TRAX
Description unavailable
More →TRDA
Description unavailable
More →